Binaytara

OncoBlast-Best of Hematology and Breast Cancer I

This CME-accredited activity, Best of Hematology and Breast Cancer I, is designed to offer practical insights into hematology and breast cancer care by educating clinicians involved in cancer care. This activity is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care of breast cancer.

Course Accreditations

Course Summary

Events Starts	Events Ends
1/1/2025	12/31/2025

Faculty

Manpreet Chadha (MD)

Dr. Manpreet Chadha is a highly respected medical oncologist specializing in breast medical oncology, with board certifications from the American Board of Internal Medicine in Medical Oncology. With a compassionate, patient-centered care philosophy, Dr. Chadha emphasizes comprehensive, evidence-based treatment combined with informed decision-making and multidisciplinary coordination. Her approach ensures that patients and their families feel supported and empowered throughout their care journey. Dr. Chadha completed her fellowship in Medical Oncology at Roswell Park Cancer Institute in 2008, following a residency in Internal Medicine at Erie County Medical Center and medical education at Maulana Azad Medical College. She is affiliated with several leading Arizona medical facilities, including Banner Boswell Medical Center, Banner Thunderbird Medical Center, and Banner Estrella Medical Center.

Disclosure

Financial relationships No, I have not had a financial relationship with an ineligible company within the past 24 months.

Geoffrey Shouse (D.O., Ph.D.)

Geoffrey Shouse, D.O., Ph.D.'s is a board certified hematologist/oncologist and physician scientist who focuses his research on eliminating the barriers of lymphoma cure. He is the primary investigator on numerous clinical trials including utilizing cutting edge treatments to more effectively treat lymphoma. These include cell therapies, molecular targeted therapies and immunotherapy. In addition, he leads studies designed to improve outcomes in older adults facing the sometimes daunting toxicities of lymphoma therapy. Finally, he designs and implements clinical trials focused on enhanced access and recruitment of underrepresented minorities. Dr. Shouse's fascination with molecular biology led him to hematology and oncology as a career. He earned a Ph.D. in cell, molecular and developmental biology at the University of California Riverside, and went on to study medicine at Western University of Health Sciences in Pomona, California. He continued his residency and fellowship training at Loma Linda University Medical Center, with additional fellowship training at City of Hope in stem cell transplant and cellular therapy.

Disclosure

Rahul Banerjee (MD, FACP)

Dr. Rahul Banerjee, MD, FACP, is an Assistant Professor in the Division of Medical Oncology at the University of Washington (Seattle, WA); he also holds a faculty appointment at the Fred Hutchinson Cancer Center. He previously completed his hematology/oncology fellowship and advanced BMT/CAR-T fellowship at the University of California San Francisco (San Francisco, CA). His clinical interests are in multiple myeloma, AL amyloidosis, and CAR-T therapy. His research interests are in toxicity management, digital health, and the patient experience.

Disclosure

Financial relationships Yes, I have had a financial relationship with an ineligible company within the past 24 months. Financial relationships: Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Adaptive Biotech Topic: Consulting Attribution: Self Type of financial relationship: Independent contractor Ineligible company: BMS Topic: Consulting Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Caribou Biosciences Topic: Consulting Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Genentech/Roche Topic: Consulting Attribution: Self Type of financial relationship: Independent contractor Ineligible company: GSK Topic: Consulting Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Karyopharm Topic: Consulting Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Legend Biotech Topic: Consulting Attribution: Self Type of financial relationship: Independent contractor Ineligible company: JNJ / Janssen Topic: Consulting Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Pfizer Topic: Consulting Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Sanofi Topic: Consulting Attribution: Self Type of financial relationship: Independent contractor Ineligible company: SparkCures Topic: Consulting Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: Abbvie Topic: Research Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: BMS Topic: Research Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: JNJ / Janssen Topic: Research Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: Novartis Topic: Research Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: Pack Health Topic: Research Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: Prothena Topic: Research Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: Sanofi Topic: Research

Oliver Batson (MD)

Raised on the East Coast, Dr. Batson graduated from the Johns Hopkins School of Medicine in 1984 and went on to complete his post-graduate education in Indianapolis and in Vermont. He practiced in Everett Washington for almost 25 years before relocating to eastern Washington in 2015. He is board certified in both Hematology and Medical Oncology. Besides clinical care, he has been the medical director at Providence St. Mary Regional Cancer Center since 2019 and also serves as a principal investigator for both industry and cooperative group studies available at the center. In his spare time he enjoys being with his family and working on his property, still leaving time for golf and fine Walla Walla Valey wines.

Disclosure

Financial relationships No, I have not had a financial relationship with an ineligible company within the past 24 months.

Christopher D'Angelo (MD)

Dr. Christopher D'Angelo is an Assistant Professor within the Hematology/Oncology Division at the University of Nebraska Medical Center in Omaha, NE. After graduating with a B.S. from Northwestern University in 2008, he attended the University of Illinois College of Medicine from 2009-2013 and graduated with honors. He completed a residency in Internal Medicine at the University of Chicago, Chicago, IL in 2016, followed by a hematology/oncology fellowship at the University of Wisconsin, Madison, WI in 2019. Dr. D'Angelo's clinic focuses on patients with lymphoma and multiple myeloma, and he attends on the bone marrow transplant service regularly. Dr. D'Angelo's research interests include clinical trials in lymphoma and multiple myeloma as well as translational research with collaborative partners investigating the role of the gut microbiome in the pathogenesis and treatment of lymphoma and multiple myeloma.

Disclosure

Roland Walter (MD, PhD, MS)

Dr. Walter is currently a Professor in the Translational Science and Therapeutics Division at the Fred Hutchinson Cancer Center, a Professor of Medicine in the Division of Hematology and Oncology/Department of Medicine at the University of Washington (UW), and an Adjunct Professor in the Department of Laboratory Medicine and Pathology at the UW. His research is focused on acute myeloid leukemia (AML), particularly on the improvement of antibody-based therapies via optimizing the efficacy/safety profile of existing therapeutics and through the preclinical and early clinical development of novel antigen-directed immunotherapies. In clinical studies, Dr. Walter conducts trials testing novel treatments and innovative care approaches for AML patients. Furthermore, in collaborative research, he uses large patient datasets to develop and improve diagnostic and prognostic tools for people with AML.

Disclosure

Financial relationships Yes, I have had a financial relationship with an ineligible company within the past 24 months. Financial relationships: Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: Celgene/Bristol Myers Squibb Topic: Preclinical AML drug development Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: ImmunoGen/AbbVie Topic: Preclinical AML drug development Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: Janssen Topic: Preclinical AML drug development Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: Pfizer Topic: Preclinical AML drug development Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: Jazz Topic: Clinical trial support Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: Kura Topic: Clinical trial support

Lynn Symonds (MD)

Dr. Lynn Symonds is a medical oncologist at Fred Hutchinson Cancer Center specializing in breast cancer. She sees patients at the Breast Health Clinic in South Lake Union and brings deep expertise in treating all forms of breast cancer. Her clinical focus is matched by her commitment to compassionate, individualized care. Her research background spans laboratory and clinical settings, with a current focus on translational and clinical research aimed at understanding and preventing metastasis. Inspired by early encounters with HER2-targeted therapies, Dr. Symonds has dedicated her career to advancing treatments that improve outcomes while reducing side effects. Dr. Symonds earned her undergraduate degree from Dartmouth College and her medical degree from the Geisel School of Medicine at Dartmouth. She completed her internship and residency in internal medicine, followed by a fellowship in hematology-oncology, all at the University of Washington.

Disclosure

Financial relationships No, I have not had a financial relationship with an ineligible company within the past 24 months.

O. Kenneth Macdonald (MD)

Dr. Macdonald’s career is marked by developing and honing his skills to effectively provide radiotherapy for a variety of cancer types for both females and males. Dr. Macdonald’s long-time interest in stereotactic body radiotherapy (SBRT), intensity-modulated radiotherapy (IMRT) and advanced radiotherapy techniques have inspired him to seek for ways to expand the role of radiotherapy in treating a variety of primary and recurrent malignancies. His participation in research groups, clinical trials, and multi-disciplinary care teams allows opportunity for patients to undergo additional courses of radiation, once thought impractical, to achieve control, relief and confidence, in addition to the standard radiotherapy options. In his spare time, Dr. Macdonald enjoys exploring the world with his wife, spending time with his 5 children, participating in a variety of fitness activities, barbecuing, and cheering for his favorite sports teams.

Disclosure

Financial relationships No, I have not had a financial relationship with an ineligible company within the past 24 months.

Norah Lynn Henry (MD, PhD)

Dr. Norah Lynn Henry is a board-certified medical oncologist and Professor of Internal Medicine at the University of Michigan, where she currently serves as the Interim Division Chief of Hematology/Oncology. She specializes in the treatment of breast cancer across all stages, with a clinical focus on providing personalized, evidence-based care that supports both effective treatment and quality of life. Dr. Henry received her medical degree from Washington University School of Medicine in 2001, completed her internal medicine residency at Brigham and Women’s Hospital in 2004, and a fellowship in Hematology/Medical Oncology at the University of Michigan Health System in 2007. From 2016 to 2019, she served on the faculty at the University of Utah’s Huntsman Cancer Institute before returning to Michigan. Her research is dedicated to advancing individualized breast cancer therapies and improving symptom and side effect management. She actively collaborates with laboratory scientists to translate preclinical research into clinical trials, working toward innovative, patient-centered cancer care. Dr. Henry is affiliated with several professional organizations including the American Society of Clinical Oncology (ASCO) and the SWOG Cancer Research Network. She also contributes to the Breast Oncology Research Program at the University of Michigan Rogel Cancer Center.

Disclosure

Financial relationships Yes, I have had a financial relationship with an ineligible company within the past 24 months. Financial relationships: Type of financial relationship: Other Ineligible company: AstraZeneca Topic: steering committee member for patient registry Type of financial relationship: Other Ineligible company: Myovant Sciences Topic: consultant related to relugolix

Sara Hurvitz (MD)

Sara A Hurvitz, MD, is Professor of Medicine at the University of Washington School of Medicine where she serves as Division Head of Hematology/Oncology and Professor of Medicine at the Fred Hutchinson Cancer Center where she serves as Senior Vice President of the Clinical Research Division. Dr. Hurvitz earned her MD from the University of Southern California. She served internship/residency at UCLA, was Chief Resident of internal medicine and completed a hematology-oncology fellowship at UCLA in 2006. Dr. Hurvitz received board-certification in internal medicine, hematology, and medical oncology. Dr. Hurvitz led the breast cancer clinical trials program at UCLA for 17 years and was Medical Director of the Jonsson Comprehensive Cancer Center until 2023 when she accepted a leadership position at UW/FHCC. Dr. Hurvitz has won numerous awards over the past few years, among them the Marni Levine Memorial Breast Cancer Research Award 2008 through 2015 and the European Society of Medical Oncology Breast Cancer Award in 2023. She has an active clinical practice specializing in the treatment of women with breast cancer. She is involved in designing, implementing and leading multiple national and international clinical trials testing new targeted therapies.

Disclosure

Financial relationships Yes, I have had a financial relationship with an ineligible company within the past 24 months. Financial relationships: Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: Arvinas, Astra Zeneca, Bayer, Celcuity, Cytomx, Daiichi-Sankyo, Dantari, Dignitana, Genentech/Roche, G1-Therapeutics, Gilead, Greenwich Life Sciences Inc, GSK, Immunomedics, Eli Lilly, Macrogenics, Novartis, OBI Pharma, Orinove, Orum, Pfizer Topic: Breast Cancer Trials Relationship end date: 07/31/2023 Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: Phoenix Molecular Designs, Ltd., Pieris, PUMA, Radius, Samumed, Sanofi, Seattle Genetics/Seagen, Zymeworks Topic: Breast Cancer Trials Relationship end date: 07/31/2023 Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: Dantari, LOXO Topic: Breast Cancer Trials Relationship end date: 07/31/2023 Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Onclive, Curio Topic: Education

Shipra Gandhi (MD)

Dr. Shipra Gandhi is an Associate Professor of Oncology at Roswell Park Comprehensive Cancer center, specializing in treating patients with breast cancer. She completed her internal medicine residency at University at Buffalo, followed by hematology-oncology fellowship at Roswell Park Comprehensive Cancer Center. Her clinical interests are in breast cancer. Her research interests include biomarkers for response and toxicities, novel therapeutics for triple negative breast cancer and clinical outcomes by racial disparities.

Disclosure

Financial relationships Yes, I have had a financial relationship with an ineligible company within the past 24 months. Financial relationships: Attribution: Self Type of financial relationship: Other Ineligible company: Astrazeneca Topic: T-DXD Relationship end date: 07/15/2022 Attribution: Self Type of financial relationship: Other Ineligible company: Novartis Topic: Ribociclib Relationship end date: 11/27/2023 Type of financial relationship: Professional Services Ineligible company: OncLive Type of financial relationship: Professional Services Ineligible company: MedPage Today Type of financial relationship: Professional Services Ineligible company: Aptitude Health

Tara Graff (DO, MS)

Dr. Graff obtained her master’s degree in Immunology from Loyola University in Chicago and earned her Doctor of Osteopathic Medicine credentials from Lake Erie College of Osteopathic Medicine in Bradenton, Florida in 2009. She completed her residency training in Internal Medicine and a fellowship in Hematology and Oncology at the Medical College of Wisconsin at Froedtert Memorial Lutheran Hospital. She has led several clinical research projects and has published many original oncology and hematology articles. Dr. Graff is board certified in both Internal Medicine and Medical Oncology. Dr. Graff has worked at Mission Cancer and Blood in Des Moines IA for the over 9 years specializing in CLL and NHL. Dr. Graff serves on the BMS National CAR-T Cell Advisory Board for Lymphoma as well as sitting on multiple National Lymphoma Advisory Boards, NHL Advisory Council and LBCL Steering Committee. She is a member of ECOG Clinical Trial Organization, Lymphoma Working Committee for the CIBMTR and sits on the Lymphoma Research Foundation (LRF). She has paired with LLS doing patient education for rural cancer patients as well as CAR-T and bispecific education for community oncologists. Dr. Graff is the cellular therapy lead for Exigent Research as well as co-chair for the malignant hematology council for Exigent Research. She is an educational speaker for many companies and is trained in MRD interpretation through Adaptive Biotech. Dr. Graff serves as the Primary Investigator for multiple clinical trials both past and present and is Physician Champion and Lead for Mission Cancer and Blood Clinical Trials Program. She is the recipient of the 2023 Q2 Targeted Oncology ICONS Award and has been Nominated for Visionary of the Year by the leukemia and lymphoma society for 2024.

Disclosure

Financial relationships Yes, I have had a financial relationship with an ineligible company within the past 24 months. Financial relationships: Attribution: Self Type of financial relationship: Independent contractor Ineligible company: AZ Topic: Advisor/education Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Adaptive Topic: Advisor/education Attribution: Self Type of financial relationship: Independent contractor Ineligible company: AbbVie Topic: Advisor/education Attribution: Self Type of financial relationship: Independent contractor Ineligible company: BMS Topic: Advisor/education Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Cellectar Topic: Advisor/education Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Genmab Topic: Advisor/education Attribution: Self Type of financial relationship: Independent contractor Ineligible company: KITE Topic: Advistor/education Attribution: Self Type of financial relationship: Independent contractor Ineligible company: ADC Therapeutics Topic: Advisor/education Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Beigene Topic: Advisor/education Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Lilly Topic: Advisor/education Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Genetench Topic: Advisor/education Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Jansen Topic: Consultant Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Pfizer Topic: Advisor

Mary (Nora) L. Disis (MD)

Dr. Mary “Nora” Disis is an expert in the immunology and immunotherapy of breast and ovarian cancers. She is dedicated to translating lab discoveries into the clinic for patients and holds several patents for targeted cancer therapies and diagnostics. Dr. Disis’ research interest lies in the discovery of new molecular targets for cancer immunotherapies, particularly vaccines and T-cell therapies. She is one of the investigators who discovered that the molecule HER-2/neu is a tumor-specific marker, or antigen. Today, many widely used cancer drugs target HER-2, and her work has led to several clinical trials testing HER-2–based cancer vaccines. Her group also studies how the immune system could be used to diagnose cancer and develops novel tests for characterizing the immune system. In addition to her research and clinical work, Dr. Disis holds many local and national leadership positions in her field.

Disclosure

Financial relationships Yes, I have had a financial relationship with an ineligible company within the past 24 months. Financial relationships: Attribution: Other Type of financial relationship: Grant Or Contract Ineligible company: Bavarian Nordic Topic: Vaccines Attribution: Other Type of financial relationship: Grant Or Contract Ineligible company: Veanna Topic: Immune therapy Attribution: Other Type of financial relationship: Grant Or Contract Ineligible company: Precigen Topic: Vaccines Attribution: Other Type of financial relationship: Grant Or Contract Ineligible company: Aston Sci Topic: Vaccines Attribution: Self Type of financial relationship: Intellectual Property Other Ineligible company: University of Washington Topic: Patents

Target Audience

Hematologists

Oncologists

Surgeons

Radiation Oncologists

Oncology residents/fellows

Oncology NPs/PAs

Oncology pharmacists

Oncology nurses

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

Choose new therapeutic options for treating benign and malignant hematologic disorders & breast cancer.

Review appropriate indications and contraindications to these therapeutic approaches.

Integrate evolving diagnostic, prognostic, and therapeutic approaches to managing hematologic disorders and breast cancer patients.

Individualize management of patients based on emerging data from clinical trials and evolving expert guidelines.